Post–myocardial infarction patients are less likely to receive statins as part of their treatment if they live with alcohol-associated liver disease, according to a new analysis presented at The Liver Meeting 2023.
The researchers also found that patients with ALD are less likely to receive other secondary preventive medications, such as beta-blockers.
For patients with ALD who received statins, the researchers found a lower mortality rate, suggesting that failure to receive statins